Similarly, other trials are evaluating the efficacy of the combined use of TT agents (vemurafenib, cobimetinib, sunitinib, erlotinib and others) with ICI (pembrolizumab, anti-PD1, atezolizumab, anti-PDL-1, ipilimumab) in melanoma, NSCLC and RCC [188,189,192]. This evidence concerns the gene CD274 and renal cell carcinoma.